Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

6 Recommendations for further research

6.1 There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have cancer and experience an acute pulmonary embolism or deep vein thrombosis. As in NICE technology appraisal guidance 261 it is recommended that further research should be carried out.

6.2 Research into the long-term treatment effects of rivaroxaban is needed.